Furthermore, the ESCORT-1st trial (73) established camrelizumab combined with chemotherapy as an effective first-line treatment in unresectable or metastatic ESCC, prolonging OS and progression-free survival (PFS) regardless of PD-L1 expression. This evidence concerns the gene CD274 and esophageal squamous cell carcinoma.